Searched for
INSULIN BRAND ACQUISITION
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 cr from Indian pharma giantsSanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...
- Lupin subsidiary acquires 9 brands South African firmLupin's subsidiary, in partnership with ImpiloVest, has acquired nine brands from MNI in South Africa, enhancing its portfolio in complemen...
- Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...
- Eris Lifesciences acquires Biocon Biologics domestic branded formulation business for Rs 1,242 croreAs part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...
- Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...
- Buy Eris Lifesciences, target price Rs 780: Motilal Oswal Financial ServicesEris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceutica...
- Biocon's growth drivers are in place: 5 reasons it is this week's stock pickImproving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...
- Eris Lifesciences enters licensing deal with Biocon for insulin glargineThe launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
- Temasek, TrueNorth-CPPIB seek to invest in Biocon BiologicsEye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.
- Torrent close to buying women healthcare portfolio of Swiss pharma major NovartisSources say cos have already signed a business transfer deal for the domestic women healthcare portfolio, which is worth around Rs 300 cror...
- Sun Pharmaceuticals to sell some low priority Ranbaxy brandsThe Ranbaxy brands that Sun is looking to sell rake in about Rs 115 crore in annual sales and the company is expecting a valuation of about...
- Sanofi charts India-specific strategy to boost shareFrench drug maker Sanofi says it is considering an India-specific strategy to increase its share in the country’s Rs 65,000-crore drug mark...
- Local manufacturing can boost margins for LupinFor a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...
- Eli Lilly's to bet on original drugs to triple sales in India over next 5 yearsUnlike other foreign drugmakers, it plans to stay away from acquisition of local firms or branded generics to boost its market share.
- Biocon Q4 profit zooms to Rs 81 croreBiotechnology major Biocon's net profit for the fourth quarter rose sharply after revenues increased and a forex loss of Rs 41.4 crore had ...
- Biocon eyes more buys to boost growthIndia's top biotechnology firm, Biocon Ltd, is looking at overseas acquisitions for about $10 million to boost its sales globally and gain ...
Load More
